CN118903170A - Application of trachelospermin in preparation of diarrhea treatment medicine - Google Patents

Abstract

The invention discloses application of trachelospermi glycoside in preparation of a medicament for treating diarrhea. Compared with the prior art, the invention discovers that the trachelospermi glycoside can treat diarrhea for the first time. Proved by experimental study, the trachelospermi glycoside can effectively reduce the loose stool rate and the diarrhea rate of diarrhea mice, and improve the weight, the feed intake and the water intake of the diarrhea mice. Therefore, the trachelospermine glycoside can be used for treating diarrhea, and has remarkable effect. In conclusion, the trachelospermi glycoside can be used for preparing the medicine for treating diarrhea, and has good market potential and value.

Description

Application of trachelosidin in the preparation of drugs for treating diarrhea

Technical Field

The invention belongs to the technical field of new drug applications, and particularly relates to the application of trachelosidoside in the preparation of drugs for treating diarrhea.

Background Art

Diarrhea is a common digestive system disease, which is defined as more bowel movements per day than normal, and the stool is thin and has increased water content, which may contain undigested food or pus, blood, and mucus. Diarrhea can be divided into acute diarrhea and chronic diarrhea. Acute diarrhea is usually related to intestinal infection, while chronic diarrhea may be caused by a variety of reasons, including intestinal diseases, malabsorption and digestion, tumors, etc.

Symptoms of diarrhea include abdominal pain, increased frequency of diarrhea, fever, and weight loss. Abdominal pain usually occurs at the beginning of diarrhea and may be relieved after a bowel movement. Acute diarrhea may cause a significant increase in the number of bowel movements per day, with loose stools that may sometimes contain blood and pus. Diarrhea may also cause fever, which is especially common in infectious diarrhea such as acute bacillary dysentery. Chronic diarrhea, such as caused by gastrointestinal malignancies, may affect nutrient absorption and lead to weight loss.

There are many causes of diarrhea, including disease factors, drug factors, genetic factors, environmental factors and lifestyle. Among the disease factors, there are food poisoning, acute intestinal infection, and inflammatory bowel disease. Treatment of diarrhea needs to be based on the cause. For acute diarrhea, replenishing fluids and electrolytes to prevent dehydration is key. For diarrhea caused by infection, anti-infective drugs may be required. For chronic diarrhea, treatment is mainly targeted at the specific cause while ensuring the patient's nutritional intake. In addition, maintaining good hygiene habits, paying attention to water safety, and avoiding drug abuse can also help prevent the occurrence of diarrhea.

In short, diarrhea is a common digestive system disease with diverse symptoms and complex causes. For the treatment and prevention of diarrhea, it is necessary to comprehensively consider the cause, symptoms and personal situation and take targeted measures. At present, no relevant research has been found that trachelosyl glycoside can treat diarrhea.

Summary of the invention

Purpose of the invention: In order to solve the defects of the prior art, the present invention provides the use of trachelosidone in the preparation of drugs for treating diarrhea.

Technical solution: In order to achieve the above-mentioned invention object, the present invention adopts the following technical solution:

In a first aspect, the present invention provides the use of trachelosidoside in the preparation of a drug for treating diarrhea.

Specifically, the diarrhea is diarrhea caused by Escherichia coli infection.

As a preferred embodiment, the trachelosidoside is used as the sole active ingredient in the preparation of a drug for treating diarrhea.

As a specific embodiment, the drug for treating diarrhea is an oral drug or an injectable drug.

In a second aspect, the present invention provides use of a composition comprising trachelosyl glycoside in the preparation of a diarrhea drug.

Specifically, the diarrhea is diarrhea caused by Escherichia coli infection.

As a preferred embodiment, in the composition, trachelosidoside is the only active ingredient.

As a specific embodiment, the composition comprises trachelosidoside and pharmaceutically acceptable excipients.

As a specific embodiment, the dosage form of the composition is selected from tablets, capsules, powders, granules, oral liquids or injections.

The trachelosidin described in the present invention has a molecular formula of C ₂₇ H ₃₄ O ₁₂ , a CAS number of 33464-71-0, and a chemical structural formula as shown below:

Beneficial effects: Compared with the prior art, the present invention discloses the use of trachelosidone in the preparation of drugs for treating diarrhea. The experimental study of the present invention confirms that trachelosidone can effectively reduce the loose stool rate and diarrhea rate of diarrheal mice, and increase the body weight, food intake and water intake of diarrheal mice. Therefore, trachelosidone can be used to treat diarrhea, and the effect is significant. In summary, trachelosidone can be used to prepare drugs for treating diarrhea, and has good market potential and value.

DETAILED DESCRIPTION

The technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, the conventional conditions or the conditions recommended by the manufacturer are followed. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

Example

1. Main experimental materials

MCE, sodium chloride, distilled water, Escherichia coli CMCC44108.

SPF Kunming mice were provided by Shanghai SLEX Laboratory Animal Co., Ltd./Shanghai Animal Experimental Center, Chinese Academy of Sciences, with a body weight of 20±2g.

2. Experimental methods

Fifty healthy Kunming mice were selected for the experiment. After one week of adaptation, they were randomly divided into blank group and model group according to similar body weight, with 10 mice in blank group and 50 mice in model group. The model group was intraperitoneally injected with 0.02mL/g (3×10 ⁸ CFU) of Escherichia coli CMCC44108 suspension, and the blank group was injected with the same dose of sterile saline. After 5 consecutive days, the model group was divided into model control group and trachelosyl glycoside treatment group again. The treatment groups were trachelosyl glycoside high-dose group (400mg/kg), medium-dose group (200mg/kg) and low-dose group (100mg/kg), 10 mice/group, 5 mice/cage, and gavage treatment according to the above doses. The blank group and model control group mice were gavaged with the same volume of saline, and the mice in each group were fed with 55g/cage/d of feed and 150mL/cage/d of water, and the treatment was continued for 6 days.

3. Clinical records and observations of experimental animals

The loose stools of mice in each group were observed, and the body weight, food intake, total number of defecation and number of loose stools were recorded, and the body weight growth rate and loose stool rate were calculated.

Weight growth rate = [(final weight - weight at treatment day 0) / weight at treatment day 0] × 100%;

Feed intake (g) = total amount of feed put in on the day (55g) - remaining amount on the second day;

Loose stool rate (%) = number of loose stools/total number of defecation × 100%.

4. Statistical analysis

The measurement data obtained from each group were expressed as mean ± standard deviation (x ± s), and the data were processed using DPSv7.05 software. The means between the two groups were compared using t-test, and P < 0.05 was considered statistically significant.

5. Results

5.1 Effect of trachelosidol on body weight of mice with diarrhea

The weight changes of mice in each group at 0d, 2d, 4d and 6d after treatment were counted, and the weight growth rate was calculated. The results are shown in Table 1 below.

Table 1 Body weight changes of mice in each group ( n＝10)

Note: Compared with the blank group, *P<0.05; compared with the model group, #P<0.05.

From the results in Table 1 above, it can be seen that compared with the blank group, at 0 days of treatment, the body weight of mice in the model control group, the high-dose group, the medium-dose group and the low-dose group of trachelosidone was significantly reduced, indicating that the model was successfully established. Compared with the model group, after 6 days of treatment, the body weight growth rate of mice in the high-dose group, the medium-dose group and the low-dose group of trachelosidone was significantly increased, especially in the high-dose group of trachelosidone, whose body weight growth rate was close to that of the blank group.

5.2 Effect of trachelosidol on food intake in mice with diarrhea

According to the above method, the total amount of feed given to each group of mice per day and the remaining amount were counted, and the food intake at 0d, 2d, 4d and 6d after treatment was calculated. The results are shown in Table 2 below.

Table 2 Food intake of mice in each group ( n＝10)

Note: Compared with the blank group, *P<0.05; compared with the model group, #P<0.05.

From the results in Table 2 above, it can be seen that compared with the blank group, at 0 days of treatment, the food intake of mice in the model control group, the high-dose group, the medium-dose group and the low-dose group of trachelosidone was significantly reduced, indicating that the model was successfully established. Compared with the model group, after 2 days of treatment, the food intake of the high-dose group of trachelosidone increased significantly, after 4 days of treatment, the food intake of the medium-dose group of trachelosidone also increased significantly, and after 6 days of treatment, the food intake of mice in the high-dose group, the medium-dose group and the low-dose group of trachelosidone increased significantly, especially the high-dose group of trachelosidone, whose food intake was close to that of the blank group.

5.3 Effect of trachelosyl glycosides on the loose stool rate in mice with diarrhea

According to the above method, the total number of defecation and loose stools of each group of mice per day were counted, and the loose stool rate was calculated. The results are shown in Table 3 below.

Table 3 The loose stool rate of mice in each group ( n＝10)

Note: Compared with the blank group, *P<0.05; compared with the model group, #P<0.05.

From the results in Table 3 above, it can be seen that compared with the blank group, at 0 days of treatment, the loose stool rates of mice in the model control group, the high-dose group, the medium-dose group and the low-dose group of trachelosidone were significantly increased, indicating that the model was successfully established. Compared with the model group, after 2 days of treatment, the loose stool rate of mice in the high-dose group of trachelosidone was significantly reduced, and after 4 and 6 days of treatment, the loose stool rates of mice in the high-dose group, the medium-dose group and the low-dose group of trachelosidone were significantly reduced.

The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims (9)

1. The application of trachelosyl glycoside in the preparation of drugs for treating diarrhea. 2. The use according to claim 1, characterized in that the diarrhea is diarrhea caused by Escherichia coli infection. 3. The use according to claim 1, characterized in that the trachelosidoside is used as the sole active ingredient in the preparation of a drug for treating diarrhea. 4. The use according to claim 1, characterized in that the drug for treating diarrhea is an oral drug or an injectable drug. 5. Use of a composition comprising trachelosyl glycoside in the preparation of a drug for treating diarrhea. 6. The use according to claim 5, characterized in that the diarrhea is diarrhea caused by Escherichia coli infection. 7. The use according to claim 5, characterized in that in the composition, trachelosidoside is the only active ingredient. 8. The use according to claim 5, characterized in that the composition comprises trachelosidoside and pharmaceutically acceptable excipients. 9. The use according to claim 5, characterized in that the dosage form of the composition is selected from tablets, capsules, powders, granules, oral liquids or injections.